A client recently started cenobamate and the dose was increased faster than the prescribed titration. The client now has fever, diffuse rash, facial swelling, and enlarged lymph nodes. Which action is the priority?

1 Give the next dose with an antihistamine.
2 Continue the current dose until a routine visit.
3 Reduce the dose by half without notifying the prescriber.
4 Hold cenobamate and obtain urgent evaluation for drug reaction with eosinophilia and systemic symptoms. ✓ Correct answer

Explanation

Fever, rash, facial edema, and lymphadenopathy after rapid cenobamate titration can signal DRESS, a potentially fatal multiorgan hypersensitivity reaction requiring immediate discontinuation evaluation.

Next question on this topicA nurse is reviewing the morning lab results for an adult client receiving warfarin for at…

In-depth explanation

Quick answer
Treat rash plus systemic symptoms during cenobamate titration as possible DRESS.

Why this is correct
Cenobamate must be started low and titrated slowly. Antihistamine or a partial dose reduction does not make ongoing exposure safe when DRESS is suspected.

Easy analogy or mental picture
Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.

Memory hook
Drug, urgent cue, protective action, and reassessment endpoint.

NCLEX decision rule
Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.

Why the other choices are wrong
Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.

References

1DailyMed: XCOPRI (cenobamate)DRESS risk, required slow titration, hypersensitivity warning, and urgent discontinuation evaluation

Clinical scenario

Medication-safety review
Verify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.

Browse all questions No login required

Master the NCLEX-RN with MyMerci

Thousands of NCLEX-style questions with detailed rationale — in your language. Track your progress and study smarter.

Start for free

App Store Google Play

Read in another language: English 한국어 日本語繁體中文 Tiếng Việt

For study reference only. Always follow current clinical guidelines and your institution’s protocols.

성장을 멈추지 마세요

A client recently started cenobamate and the dose was increased faster than the prescribed titration. The client now has fever, diffuse rash, facial swelling, and enlarged lymph nodes. Which action is the priority?

In-depth explanation

Clinical scenario

Master the NCLEX-RN with MyMerci